Addex Therapeutics Ltd, a clinical-stage pharmaceutical company, announced the initiation of a phase 2a clinical study with dipraglurant as a potential treatment for blepharospasm, a type of dystonia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results